• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对液态制剂中油酸诱导的抗体聚集的缓解策略。

Mitigation Strategies against Antibody Aggregation Induced by Oleic Acid in Liquid Formulations.

机构信息

Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zürich, 8093 Zürich, Switzerland.

Cilag GmbH International, a Division of Johnson & Johnson TDS-Biologics, Analytical Development, 8200 Schaffhausen, Switzerland.

出版信息

Mol Pharm. 2024 Nov 4;21(11):5761-5771. doi: 10.1021/acs.molpharmaceut.4c00754. Epub 2024 Oct 23.

DOI:10.1021/acs.molpharmaceut.4c00754
PMID:39444106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11539069/
Abstract

Polysorbates 20 and 80 (PS20 and PS80) are commonly used in the formulations of biologics to protect against interfacial stresses. However, these surfactants can degrade over time, releasing free fatty acids, which assemble into solid particles or liquid droplets. Here, we apply a droplet microfluidic platform to analyze the interactions between antibodies and oleic acid, the primary free fatty acid resulting from the hydrolysis of PS80. We show that antibodies adsorb within seconds to the polar oleic acid-water interface, forming a viscoelastic protein layer that leads to particle formation upon mechanical rupture. By testing two different monoclonal antibodies of pharmaceutical origin, we show that the propensity to form a rigid viscoelastic layer is protein-specific. We further demonstrate that intact PS80 is effective in preventing antibody adsorption at the oleic acid-water interface only at low antibody concentrations and low pH, where oleic acid is fully protonated. Importantly, introduction of the amino acid l-arginine prevents the formation of the interfacial layer and protein particles even at high antibody concentrations (180 mg mL). Overall, our findings indicate that oleic acid droplets in antibody formulations can lead to the formation of protein particles via an interface-mediated mechanism. Depending on the conditions, intact PS80 alone might not be sufficient to protect against antibody aggregation. Additional mitigation strategies include the optimization of protein physicochemical properties, pH, and the addition of arginine.

摘要

聚山梨酯 20 和 80(PS20 和 PS80)常用于生物制剂的配方中,以保护其免受界面张力的影响。然而,这些表面活性剂会随着时间的推移而降解,释放出游离脂肪酸,这些脂肪酸会组装成固体颗粒或液滴。在这里,我们应用液滴微流控平台来分析抗体与油酸之间的相互作用,油酸是 PS80 水解产生的主要游离脂肪酸。我们发现,抗体在几秒钟内就会吸附到极性的油酸-水界面上,形成一个粘弹性的蛋白质层,当受到机械破坏时会形成颗粒。通过测试两种不同的、源自药物的单克隆抗体,我们表明形成刚性粘弹性层的倾向是蛋白质特异性的。我们进一步证明,完整的 PS80 只有在低抗体浓度和低 pH 值(此时油酸完全质子化)下,才能有效防止抗体在油酸-水界面上的吸附。重要的是,引入氨基酸 l-精氨酸甚至在高抗体浓度(180mg/mL)下也能防止界面层和蛋白质颗粒的形成。总的来说,我们的研究结果表明,抗体制剂中的油酸液滴可能通过界面介导的机制导致蛋白质颗粒的形成。根据具体情况,完整的 PS80 本身可能不足以防止抗体聚集。其他缓解策略包括优化蛋白质的物理化学性质、pH 值以及添加精氨酸。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/06e9f164aca5/mp4c00754_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/29d471fc4831/mp4c00754_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/679cfc8fe4db/mp4c00754_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/d188c6ab044d/mp4c00754_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/1045208df197/mp4c00754_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/43a9710afee7/mp4c00754_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/06e9f164aca5/mp4c00754_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/29d471fc4831/mp4c00754_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/679cfc8fe4db/mp4c00754_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/d188c6ab044d/mp4c00754_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/1045208df197/mp4c00754_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/43a9710afee7/mp4c00754_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77b/11539069/06e9f164aca5/mp4c00754_0006.jpg

相似文献

1
Mitigation Strategies against Antibody Aggregation Induced by Oleic Acid in Liquid Formulations.针对液态制剂中油酸诱导的抗体聚集的缓解策略。
Mol Pharm. 2024 Nov 4;21(11):5761-5771. doi: 10.1021/acs.molpharmaceut.4c00754. Epub 2024 Oct 23.
2
A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.全油酸聚山梨酯 80 的综合评估:游离脂肪酸粒子形成、界面保护和氧化降解。
Pharm Res. 2021 Mar;38(3):531-548. doi: 10.1007/s11095-021-03021-z. Epub 2021 Mar 12.
3
Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.在受到界面扩张压力时,用 PS20 和 PS80 配制的 IgG1 mAbs 中蛋白颗粒形成的比较。
AAPS PharmSciTech. 2023 Apr 20;24(5):104. doi: 10.1208/s12249-023-02561-4.
4
Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.聚山梨酯 80 的水解和氧化对单克隆抗体聚集的影响比较。
J Pharm Sci. 2020 Jan;109(1):633-639. doi: 10.1016/j.xphs.2019.10.069. Epub 2019 Nov 20.
5
Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.聚山梨酯酯级分的特性及其对蛋白药物产品稳定性的影响。
Mol Pharm. 2020 Jul 6;17(7):2345-2353. doi: 10.1021/acs.molpharmaceut.0c00093. Epub 2020 Jun 5.
6
Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations.溶血磷脂酰胆碱作为注射用单克隆抗体制剂的界面稳定剂。
Eur J Pharm Biopharm. 2024 Nov;204:114514. doi: 10.1016/j.ejpb.2024.114514. Epub 2024 Sep 26.
7
Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.脂肪酸可诱导单克隆抗体制剂中蛋白质颗粒的形成。
J Pharm Sci. 2022 Mar;111(3):655-662. doi: 10.1016/j.xphs.2021.10.008. Epub 2021 Oct 16.
8
Complex Micellization Behavior of the Polysorbates Tween 20 and Tween 80.聚山梨酯 20 和聚山梨酯 80 的复杂胶束化行为。
Mol Pharm. 2021 Aug 2;18(8):3147-3157. doi: 10.1021/acs.molpharmaceut.1c00406. Epub 2021 Jul 12.
9
Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.常规和新型表面活性剂的界面吸附现象差异与单抗的界面稳定性变化有关。
Mol Pharm. 2022 Sep 5;19(9):3100-3113. doi: 10.1021/acs.molpharmaceut.2c00152. Epub 2022 Jul 26.
10
What Makes Polysorbate Functional? Impact of Polysorbate 80 Grade and Quality on IgG Stability During Mechanical Stress.什么使聚山梨酯具有功能性?机械应力下聚山梨酯 80 级和质量对 IgG 稳定性的影响。
J Pharm Sci. 2020 Jan;109(1):871-880. doi: 10.1016/j.xphs.2019.10.015. Epub 2019 Oct 12.

引用本文的文献

1
Assessing subvisible particle risks in monoclonal antibodies: insights from quartz crystal microbalance with dissipation, machine learning, and in silico analysis.评估单克隆抗体中的亚可见颗粒风险:来自具有耗散功能的石英晶体微天平、机器学习和计算机模拟分析的见解。
MAbs. 2025 Dec;17(1):2501629. doi: 10.1080/19420862.2025.2501629. Epub 2025 May 11.
2
Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives.生物治疗药物中的聚山梨酯降解酶——现状与未来展望
Front Bioeng Biotechnol. 2025 Jan 10;12:1490276. doi: 10.3389/fbioe.2024.1490276. eCollection 2024.

本文引用的文献

1
Real-Time Observation of Protein Aggregation at Liquid-Liquid Interfaces in a Microfluidic Device.在微流控装置中实时观察液-液界面处的蛋白质聚集。
Small. 2024 Nov;20(45):e2401085. doi: 10.1002/smll.202401085. Epub 2024 Aug 22.
2
Reexamining the diverse functions of arginine in biochemistry.重新审视精氨酸在生物化学中的多种功能。
Biochem Biophys Res Commun. 2024 Apr 23;705:149731. doi: 10.1016/j.bbrc.2024.149731. Epub 2024 Feb 27.
3
Effects of arginine in therapeutic protein formulations: a decade review and perspectives.
精氨酸在治疗性蛋白质制剂中的作用:十年回顾与展望
Antib Ther. 2023 Oct 12;6(4):265-276. doi: 10.1093/abt/tbad022. eCollection 2023 Oct.
4
Comparison of the Protective Effect of Polysorbates, Poloxamer and Brij on Antibody Stability Against Different Interfaces.聚山梨酯、泊洛沙姆和脂肪醇聚氧乙烯醚对抗体在不同界面上稳定性的保护作用比较
J Pharm Sci. 2023 Nov;112(11):2853-2862. doi: 10.1016/j.xphs.2023.06.004. Epub 2023 Jun 7.
5
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.美国批准的商业化高浓度抗体药物产品的系统评价:制剂组成、剂型设计和初级包装考虑因素。
MAbs. 2023 Jan-Dec;15(1):2205540. doi: 10.1080/19420862.2023.2205540.
6
Antibodies Adsorbed to the Air-Water Interface Form Soft Glasses.抗体吸附在气液界面形成软玻璃。
Langmuir. 2023 Jun 6;39(22):7775-7782. doi: 10.1021/acs.langmuir.3c00616. Epub 2023 May 24.
7
Stability Convergence in Antibody Coformulations.抗体制剂的稳定性收敛。
Mol Pharm. 2022 Nov 7;19(11):4098-4110. doi: 10.1021/acs.molpharmaceut.2c00534. Epub 2022 Oct 20.
8
Surface-Induced Protein Aggregation and Particle Formation in Biologics: Current Understanding of Mechanisms, Detection and Mitigation Strategies.生物制品中表面诱导的蛋白质聚集和颗粒形成:对机制、检测及缓解策略的当前认识
J Pharm Sci. 2023 Feb;112(2):377-385. doi: 10.1016/j.xphs.2022.10.009. Epub 2022 Oct 9.
9
Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of Polysorbates.生物制药产品中聚山梨酯使用及特性的行业视角 第1部分:聚山梨酯处理与控制的现状及常见做法调查报告
J Pharm Sci. 2022 May;111(5):1280-1291. doi: 10.1016/j.xphs.2022.02.009. Epub 2022 Feb 22.
10
Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.脂肪酸可诱导单克隆抗体制剂中蛋白质颗粒的形成。
J Pharm Sci. 2022 Mar;111(3):655-662. doi: 10.1016/j.xphs.2021.10.008. Epub 2021 Oct 16.